Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Cytodyn down

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Mar 09, 2021 1:25pm

84 Views

Post# 32753778

RE:RE:RE:RE:Cytodyn down

It seems to me to do financing on an artificially low price is even more silly. So all the preclinical results, record breaking sales, letter to proceed and fast track designation are not facts?Before your next response yes not human data for oncology and yes controversial phase 3 NASH ( not phase 2 or 1) but CYDY is just an example how among other companies who have successfully capitalized on less facts managed to get fair valuation.
Just look at many examples on this board rather than being focused on THTX's valuation.
There is a discrepancy no matter how we look at it.

jfm1330 wrote: The question to ask is if you are the CEO of a company, do you want to promote it with real facts or on non facts, hope, promises? Also, higher SP does not mean better financing deal. Cytodyn were never able to finance since they left the penny stock area. Thera had to do a convertible when the SP was at 13$ per share. Why? Probably because nobody wanted to be part of a bought deal at such a high price. It is impossible to do a financing on an artificially high SP. The convertible should have been a selling signal for me back then, but I did not understand it back then.

scarlet1967 wrote: CYDY started their campaign for their one hit wonder drug based on soft data in October 2019.
The SP rose from 0.35 cents to all time high $10 US. Since then it dropped and rose few times and now it dropped heavily due to fact they have to as per agencies request run an additional study for covid19 indication.
To date they are valued almost 4 times more than THTX. So yes you can promote soft data successfully and yes if not followed by hard data there is a price to pay.
Going back to most hated/loved subject the recent financing.
Why couldn't company promote the soft data get the SP higher and close a more feasible deal?
The least they would get of it would be even temporary( in case the cancer trial hit a the brick wall) a higher SP thus better deal, more money less dilution etc.
Promoting and marketing your business can always come handy in good or bad times.